Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Sustainability and HEalth as drivers of the rational design of fermentation processes: a novel prototype of Non-Alcoholic Beer (SHE-NAB)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Ireland
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-09-30
End date: 2027-03-30
Duration (months): 30.0
Total project cost (EUR): 249618.0
EU funding (EUR): 249618.0
Participants: 2
Project status: SIGNED

Beer is the world’s most consumed alcoholic drink but its alcohol content has a negative impact on health. The consumption of non-alcoholic beer (NAB) has rocketed recently, driven by changes in manufacturing processes and a more health-conscious consumer base. In Europe, the market size is estimated in $22 billion (2022). Despite its potential for diet improvement, the impact of NAB on health has been barely investigated. Moreover, this expanded market is not reusing its by-products properly and generates considerable waste. The aim of this project is to address this lack of information by elucidating the contribution of NAB to health, and by implementing waste valorisation practices to generate products with added value for the circular economy. By applying the latest methods in metagenomics, synthetic microbial ecology approaches and metabolism modelling, SHE-NAB will provide a proof-of-concept for the rational design of a novel NAB prototype, helping to deliver on EU health and sustainability priorities and to educate in the context of public health. After the generation of valorised waste products, we will harness the microbial potential of selected newly characterised strains with key functionalities (i.e: synthesis of bioactive molecules) to develop synthetic communities (SC) for the fermentation of NAB at small and pilot scale. By metagenomics and metabolomic data obtained during fermentation, ecological networks will be constructed to disentangle the contribution of each taxa to the traits of the final product and allowing a rational design of the SC to control fermentation processes. The final products will be assessed for health benefits using ex vivo gut models and cell assays. An effective two-way transfer of knowledge with industry will be achieved, particularly during a non-academic placement period, applying the SC developments at pilot scale and using valorised waste products for the production of healthy NAB in a commercial brewery environment.

Keywords: nutrition,food sciences
Phylogenies probing Grammar. Exploring morphosyntax at different scales of language change (PhylProGramm)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: The Human Mind and Its Compl exity
Panel description: Cognitive science, psychology, linguistics
Countries involved: Greece
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 2499925.0
EU funding (EUR): 2499925.0
Participants: 1
Project status: SIGNED

Morphosyntactic properties have long been considered a great challenge for the reconstruction of language history. On the one hand, they can establish deep genealogical relationships because they remain stable for millennia and evolve slowly in time, serving as markers for families. On the other hand, they may emerge abruptly as a result of borrowing from one language to the other or language restructuring under contact. At the same time, grammars develop common properties independently of history and geography, reflecting universal trends. Recent findings have shown that morphosyntactic variability significantly correlates with genetic variability, supporting the potential of morphosyntax to unravel both genetic and cultural evolutionary history. Yet the first attempts to reconstruct phylogenetic trees based on morphosyntactic data have been limited in terms of precision and resolution, and there are major disagreements on the genealogical stability and diffusability of morphosyntactic features. PhylProGramm aims to break new ground in linguistics by pioneering a new way to evaluate morphosyntax in terms of the historical information it contains, using phylogenetic inference methods as a tool. Based on preliminary results which have shown that trees constructed from morphosyntactic data reflect historical and geographical relationships, we devise novel computational methods that allow us to determine, in combination with rigorous linguistic evaluation, which features are conservative, prone to transfers/borrowings or reflect universal patterns at the scales of micro-variation, meso-variation and macro-variation. The investigation will lead us to formulate and explain the profile of specific units, their interactions, their organization into networks and/or hierarchies associated with different scales of variation and their representation in grammar, providing a unique window into the dynamics and typology of language change and variation.

Keywords: morphosyntax,phylogenetic inference,micro variation,meso variation,macro variation,historical linguistics,typology,theoretical linguistics,language change,language variation
Controlling cell lineage integrity to intercept tumor initiation (IGNITION)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: France
Call: ERC CONSOLIDATOR GRANTS (ERC-2024-COG, 2024)
Start date: 2025-12-01
End date: 2030-11-30
Duration (months): 60.0
Total project cost (EUR): 2156850.0
EU funding (EUR): 2156850.0
Participants: 2
Project status: SIGNED

Human tissues can tolerate a series of mutations in tumor suppressors and oncogenes without necessarily transforming. Potential for tumor initiation is not only determined by such accumulated molecular defects but also by the capacity of each cell and tissue to deal with them. Intrinsic cell plasticity – i.e. the ability to change phenotypes by accessing alternative expression programs - appears to be one of the determining factors of the penetrance of oncogenic stresses. Yet, how cell plasticity contributes to tumorigenesis remains poorly understood, in part because we can hardly access tumor initiation in humans. With IGNITION, we propose to uncover mechanisms maintaining cell lineage integrity under oncogenic stress in humans and explore their therapeutic potential to delay tumor initiation. To do so, we propose to access tumor initiation in humans using samples from the standard of care of BRCA1/2 mutation carriers. We will reconstitute entire individual trajectories up to tumor initiation, taking advantage of our privileged access to bio-banked and fresh human samples through the Curie hospital. Serial sampling for individual patients will be paired to organoid avatars, to expand our ability to observe tumor initiation events. Combining high resolution single-cell transcriptomics and epigenomics, we will identify recurrent non-genetic determinants of tumor initiation and study their potential as breaks or accelerators of tumor initiation with Cas9/CRISPR approaches in organoid models. Finally, we will test two strategies for therapeutic intervention: (i) control cell lineage integrity by restraining plasticity of the epithelial cell compartments, or (ii) targeting predispositions to transformation. Our long-term goal is to build on this integrated appreciation of tumor initiation to propose therapeutic strategies to monitor and delay tumor initiation in patients with pre-disposition to cancer.

Keywords: breast cancer,plasticity,single cell epigenomics and trancriptomics,predisposition
Development of a Cyclization-Functionalization Strategy Based on the Reactivity of Amine-Ligated Boryl Radicals (CYBO)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-11-01
End date: 2027-10-31
Duration (months): 24.0
Total project cost (EUR): 217965.12
EU funding (EUR): 217965.12
Participants: 1
Project status: SIGNED

Functionalized amines are high-value materials with numerous applications as therapeutic agents, agrochemicals and organic materials. The development of strategies for enabling the fast and divergent synthesis of these material can have a positive impact to our ability to discover, manufacture and evolve molecules of high-relevance to our society. In this proposal we present an innovative approach for the functionalization of homoallylic amines based on their coordination borane (BH3). This will provide access to novel boryl radical species that we will exploit in cyclization-functionalization cascade. This novel reactivity mode will convert the homoallylic amine into a cyclic borylated and functionalized building block that can be further diversified across the sp3 C–B bond by oxidation or Suzuki-Miyaura cross-coupling. Overall, this strategy will constitute a divergent platform for the diversification of high-value amines and also a novel retrosynthetic tactic for the preparation of high-value and structurally complex drug analogues. This research squarely fits within the expertise of the Leonori group in the generation and use of boryl radicals in synthesis and catalysis. The completion of such an innovative and ambitious project at RWTH Aachen University will be facilitated by generating, transferring, sharing and disseminating knowledge, and will enhance the Researcher future career following the training plan envisioned.

Keywords: boryl radicals,radical cyclization,radical cascade,photoredox catalysis,cross couplings
Oral delivery of encapsulated RNA nanotherapeutics for targeted treatment of ileal Crohn's disease (GENEGUT)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Ireland,Portugal,Sweden,Belgium,France,Switzerland,United Kingdom,Hungary
Call: Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet medical needs (HORIZON-HLTH-2021-TOOL-06, 2021)
Start date: 2022-10-01
End date: 2026-09-30
Duration (months): 48.0
Total project cost (EUR): 4601216.25
EU funding (EUR): 4601215.0
Participants: 9
Project status: SIGNED

Crohn’s disease is a non-communicable, global disease with an accelerating incidence (up to 23 per 100,000 persons/year) and annual health costs in excess of 5 billion euro in Europe. Despite advances in new immune modulators and biological treatment, up to 30% of patients become non-responders, highlighting the pressing need for novel, advanced therapies. GENEGUT will transform treatment of ileal Crohn’s disease (CD) by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects. The success of mRNA covid vaccines demonstrated the potential of RNA-based therapies; the challenge is to extend this revolutionary therapeutic modality to non-communicable diseases where RNA delivery has not been achieved, such as ileal CD. Delivery of RNA will be enabled by a combination approach where novel biomaterials, including amphiphilic cyclodextrins and amino polyesters (both patented by partners), designed to overcome the barriers in the gastrointestinal tract will complex the RNA within nanoparticles (NPs). Our industry partner’s novel capsule technology will ensure site-specific release of the encapsulated NPs at the diseased ileum. The RNA-nanotherapeutics (siRNA and mRNA) will modulate gene expression locally in the ileum by targeting the clinically validated (JAK/STAT) pathway and two exploratory targets, Gremlin and Adrenomedullin. Proof-of-efficacy will be demonstrated in vivo and also in a 3D multi-cellular model of ileal CD using primary human cells. GENEGUT brings together 9 partners from 8 European countries covering the lifecycle from bench to bedside, creating a network of renowned researchers, expert clinical scientists, SMEs and larger pharma companies and a patient organisation. GENEGUT will result in an oral RNA therapeutic ready for early clinical trial including coherent plans for clinical trials and regulatory submission thus enabling rapid availability for patients.

Keywords: gene therapy,ileal crohn s disease,oral rna nanotherapeutic,novel biomaterials,nanoparticles,reverse organoid,3d disease models,drug delivery,regulatory science,inflammatory bowel disease
Eco-operated, Modular, highly efficient, and flexible multi-POWERtrain for long-haul heavy-duty vehicles (EMPOWER)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Mobility
Destination: Clean and competitive solutions for all transport modes
Action type: Innovation actions
Partnership: 2ZERO (co-programmed)
Countries involved: Austria,Italy,France,Spain,Netherlands,Switzerland,Germany
Call: Modular multi-powertrain zero-emission systems for HDV (BEV and FCEV) for efficient and economic operation (2ZERO) (HORIZON-CL5-2022-D5-01, 2022)
Start date: 2023-01-01
End date: 2026-12-31
Duration (months): 48.0
Total project cost (EUR): 27008688.16
EU funding (EUR): 18034188.0
Participants: 17
Project status: SIGNED

EMPOWER addresses in full the expected outcome and scope of the HORIZON-CL5-2022-D5-01-08 topic by delivering two flexible, modular, and scalable zero-emission heavy-duty vehicles (ZE HDV) belonging to the VECTO vehicle group 9 (6×2 rigid trucks), with a gross vehicle weight equal or above 40 tons. One vehicle is powered by a Fuel Cell (FC) system and has a driving range of 750 km, while the other is powered by a battery-electric powertrain, and has a driving range of 400 km. Both vehicles will be delivered at TRL 8 by the end of the project (end of 2026) and are expected to approach the market by 2029. Within its technical activities, EMPOWER will: • design, implement and deliver technology bricks: (1) a modular vehicle system architecture, (2) a modular high voltage architecture, (3) a modular low-voltage E/E architecture, (4) a FC system with high reliability and extended operational lifetime with a modular energy storage, (5) a highly efficient e-axle, (6) an optimised thermal- and energy management, (7) an optimised HVAC system featuring CO2 as refrigerant and infrared heating panels, (8) an electrified distributed braking system, (9) digital twin models of the demonstrators, (10) an innovative Human Vehicle Interface for optimised control of the vehicle systems, featuring Vehicle-to-Grid communication and eco-routing, (11) a fleet management system for the integration of ZE HDV into the fleet, (12) an overall LCA and TCO assessment, and (13) the operation of a green hydrogen infrastructure for ZE HDV. • demonstrate the driving range and real-world operation performance of the two ZE HDV in five different long-haul and regional distribution use-cases, including cross-border corridors between different European member states. The modular and scalable EMPOWER technology is transferable to VECTO vehicle groups 4, 5, and 10, and it is designed to achieve the total cost of operation parity against the conventional 2020 baseline diesel truck by 2030, targeting a production volume above 10,000 vehicles/year.

Keywords: zero emission vehicle,fcev and bev trl 8 demonstrators,vecto vehicle group 9,e axle,digital twin,energy and thermal management,hvac,charging and hydrogen refueling,fleet management,tco
Open-Access Forecasting System of the Health Effects of Air Pollution (FORECAST-AIR)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Spain
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2023-POC, 2023)
Start date: 2024-04-01
End date: 2025-09-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

Air pollution represents a major global environmental health problem. 99% of the world population lives in locations where international air quality guidelines are not met. Overall, ambient air pollution causes 4.2 million premature deaths every year worldwide, half a million of which in Europe alone. Available early warning systems of air quality are generally based on location-specific thresholds of air pollutant concentrations, they are entirely based only on forecasts representing the physical processes of atmospheric chemistry, and they do not account for the inequalities in vulnerability of the exposed populations. The ERC-funded project FORECAST-AIR will go beyond these limitations in health early warning systems by integrating air quality forecasting, environmental epidemiology and the inequalities in vulnerability to implement a new method to issue public health alerts. Towards this aim, I will estimate epidemiological models between air pollution observations and health records disaggregated by causes of disease and sociodemographic vulnerable groups; I will use these models to transform bias-corrected air quality forecasts into heath predictions; I will analyse and compare the window of predictability of forecasts and predictions; and I will use this comparative study to assess the predictability of the resulting health early warning systems, so that they generate trust among public health authorities and end-users. If successful, FORECAST-AIR will drive innovation by creating operational, fit-for-purpose, early warning systems representing the health impacts of several air pollutants, with a special focus on vulnerable populations.
Nano electro-optomechanical programmable integrated circuits (NEUROPIC)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain,Denmark,Ireland,Portugal
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-03-01
End date: 2027-02-28
Duration (months): 48.0
Total project cost (EUR): 2999922.74
EU funding (EUR): 2999921.5
Participants: 7
Project status: SIGNED

NEUROPIC will design, build, measure, and explore a novel programmable photonic chip architecture with transformational impact potential on photonics for data centers, autonomous vehicles, quantum information processors, and much more. We will explore and pioneer programmability of large-scale photonic circuits using nanoelectromechanical technologies, which benefit from ultralow power consumption, compact footprint, and potentially faster operation than existing approaches. Building on very recent breakthroughs from the consortium partners, the nanotechnology is now in place to begin the exploration of programmable photonic chips scaled to thousands of programmable nodes. The main objectives range from sustainable and high-performance silicon nanomachining over establishing a scalable platform for ultralow-power nanoelectromechanical programmable silicon photonics to massively parallel optical interconnects. Our final goal is to use the network of independent and fully controllable nodes for neuromorphic computing to quantify the role of complexity for artificial intelligence. The objectives present a strong mutual synergy, scientific impact, and sustainability and set the foundations for four highly attractive business cases with complementary profiles in terms of risk and market size. NEUROPIC is therefore designed to address the fundamental scientific and technological questions of today whose answers hold potential for very large commercial impact in the future. Our quest comes with a new set of challenges and calls for a radically new approach to photonics. NEUROPIC unites some of the world’s leading researchers and companies in nanotechnology, photonics, advanced manufacturing, and complex systems in a risky and highly interdisciplinary research project with the ambition of founding a new paradigm of programmable silicon photonics.

Keywords: complex photonics,silicon nanotechnology,neuromorphic computing
Our goal is to raise the necessary capital to meet our main challenge - to complete the development of our innovative solar panel and launch an innovative solution in the solar market. (Energy autonomy)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 18.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

GCS has developed a unique, patented solar panel built from layers that combine perovskite, innovative materials and a thermoelectric process, which can work together and autonomously without interruption. This method overcomes existing technological obstacles in the industry and as stated above, triples the efficiency compared to the existing panels used in today's market. The company's vision is to develop technologies that will enable energy autonomy for everyone. The development plan of the prototype was prepared in collaboration with scientists and solar experts from the IMOMEC laboratories in Belgium and the company's activities focused on the European and American markets. Our goal is to raise the necessary capital to meet our main challenge - to complete the development of our innovative solar panel and launch an innovative solution in the solar market. GCS invention ID Israeli patent, number 297568 and worldwide protection by PCT/051092 Heat is one of the biggest obstacles in generating electricity with solar panels. As the temperature gets higher, the efficiency of the panels will be lower, (solar panels in the Upstate New York area will be more efficient than southern areas). GCS turned the obstacle into an advantage by generating additional electricity with thermoelectric technology, using the heat in the system, and turning it into electricity in the same current by collecting it with a double electrode. The unique system built from layers combining a Phot-Voltaic (PV) layer and a thermoelectric layer, each of which can work autonomously without interruption; in addition to combining has many advantages. The PV layer works better after removing and transferring heat to thermoelectric and being less damaged by heat and the thermoelectric layer is not exposed to direct sunlight, therefore its durability is guaranteed for many years. The panel works with an efficiency of about 48% that makes it a revolutionary product.

Keywords: renewable energy sources energy efficiency solar thermal